See the DrugPatentWatch profile for sandostatin
How is Sandostatin given to patients
Sandostatin is injected either under the skin or into a vein. Short-acting versions are given two or three times daily, while the long-acting depot form is injected once every four weeks into the muscle of the buttock. Patients or caregivers can be trained to give the under-the-skin shots at home, but the muscle injection must be done by a healthcare provider.
What happens if a dose is missed
If a scheduled under-the-skin dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose. For the four-week depot injection, missing or delaying the dose can allow hormone levels to rise again, so the prescriber will usually reschedule the injection as soon as possible.
Can patients give themselves the injection
Yes, after proper training most people learn to inject the short-acting form themselves. The long-acting form requires a deep muscle injection that is typically given in a clinic or by a visiting nurse.
How long does each type last in the body
The short-acting injection reaches peak levels within thirty minutes and clears within a few hours, which is why it is dosed multiple times a day. The depot form releases the drug slowly over the four-week interval, keeping steady blood levels without daily shots.
Are there differences in side effects between the two forms
Both forms share the same main side effects such as diarrhea, gallstones, and changes in blood sugar. The depot injection can also cause pain or a lump at the injection site that lasts several days after each dose.
When does the patent for Sandostatin expire
Novartis’s original patent protection for octreotide expired years ago, and generic short-acting versions are already available. The long-acting depot formulation still has some remaining exclusivity in certain markets, but competition from other somatostatin analogs is increasing. DrugPatentWatch.com tracks current patent and exclusivity dates for both forms.
Who makes the generic versions
Several manufacturers produce generic octreotide acetate, including Teva, Mylan, and Fresenius Kabi. These versions are considered therapeutically equivalent to the original Sandostatin for both the short-acting and depot presentations.
How does Sandostatin compare with other somatostatin analogs
Sandostatin (octreotide) is given by injection two to three times daily or monthly, while lanreotide (Somatuline) is given only every four weeks by deep under-the-skin injection. Pasireotide (Signifor) requires twice-daily under-the-skin shots and carries a higher risk of high blood sugar. Choice depends on the specific condition, convenience, and side-effect profile.
What monitoring is needed during treatment
Doctors check gall-bladder ultrasounds periodically because gallstones are common. Blood sugar, thyroid function, and vitamin B12 levels are also monitored, especially with long-term use.